December 15th, 2015

Week in Review: BioKangtai Acquires China Rights to AstraZeneca's COVID-19 Vaccine

COVID-19 Pandemic • BioKangtai, a Guangdong vaccine company, in-licensed rights to develop, manufacture and market AstraZeneca's COVID-19 vaccine in China; • Shanghai Fosun Pharma has dosed the first 72 participants in a China Phase I trial of an mRNA vaccine for COVID-19; Deals and Financings • Biogen announced a $2 billion deal to partner Denali's novel Parkinson's Disease therapy with Denali co-marketing the candidate in the US and China; • Sherpa Healthcare Partners of Beijing closed its first US dollar fund with $200 million in capital; • Shanghai Lepu Biotech closed a $186 million Series B round to support its portfolio of affordable cancer immunotherapies; • Nanjing Simcere Pharma in-licensed China rights to a myelopreservation candidate from North Carolina's GI Therapeutics in a $170 million deal; • ABM Therapeutics of Shanghai completed a $20 million Series A+ round for small molecule cancer candidates that cross the blood-brain barrier; • VistaGen of South San Francisco received a $5 million payment from Shanghai's EverInsight, an in-licensing fee for a novel anxiety treatment;  Trials and Approvals • CStone Pharma announced its anti-PD-L1 mAb, met the primary progression-free survival endpoint in a China Phase III trial for NSCLC; • NeuPharma of Suzhou BioBay started a Phase II trial of a treatment for recurrent glioblastoma multiforme; • Zai Lab of Shanghai said China's NMPA granted priority review for its ripretinib NDA in GIST; • Suzhou Innovent dosed the first patient in a China Phase I clinical trial of its CD47/PD-L1 bispecific antibody in patients with advanced malignancies. Stock Symbols: (NSDQ: BIIB) (NSDQ: DNLI) (NSDQ: GTHX) (NSDQ: VTGN) (SHZ: 300601) (NYSE: AZN) (SHA: 600196; HK; 02196) (HK: 2616) (NSDQ: ZLAB) (HK: 01801) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.